Epilepsy trials in Argentina
6 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleInvestigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- Where
- Córdoba, Mendoza
- Age
- 4 years to 55 years
- People
- 252 worldwide
- Run by
- SK Life Science, Inc.
See details and how to joinNCT05219617 - Phase 3Taking peopleA Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- Where
- Buenos Aires, San Miguel de Tucumán
- Age
- 12 years and over
- People
- 160 worldwide
- Run by
- Xenon Pharmaceuticals Inc.
See details and how to joinNCT05667142 · EU 2022-502286-16-00 - Phase 3Taking peopleA Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
- Where
- Buenos Aires, C.a.b.a., Córdoba, San Luis, San Miguel de Tucumán
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Xenon Pharmaceuticals Inc.
See details and how to joinNCT05716100 · EU 2022-502281-25-00 - Phase 3Enrolling by invitationAn Open-label Study of XEN1101 in Epilepsy
- Where
- Buenos Aires, Córdoba, San Juan Bautista, San Luis, San Miguel de Tucumán
- Age
- 12 years and over
- People
- 880 worldwide
- Run by
- Xenon Pharmaceuticals Inc.
See details and how to joinNCT05718817 · EU 2022-502282-24-00 - Phase 3Taking peopleA Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
- Where
- Buenos Aires, Córdoba, San Luis
- Age
- 2 years and over
- People
- 150 worldwide
- Run by
- Epygenix
See details and how to joinNCT04462770 · EU 2024-518628-57-00 - Phase 2Enrolling by invitationLong-term Safety and Tolerability of BHV-7000
- Where
- Balvanera, Buenos Aires, Ciudad Autónoma de Buenos Aires, Córdoba, San Miguel de Tucumán
- Age
- 18 years to 75 years
- People
- 660 worldwide
- Run by
- Biohaven Therapeutics Ltd.
See details and how to joinNCT06443463 · EU 2023-508813-18-00